JJP-1212 / JJP Biologics - LARVOL DELTA

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89) (Businesswire) - "JJP Biologics...announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Application to conduct a phase I clinical study in healthy participants (EudraCT: 2023-508661-33-00) with their potential first-in-class anti-CD89 antagonist, JJP-1212....The Phase I trial will be executed in Poland....The study results will provide data on the safety and tolerability of JJP-1212, and full PK/PD profiles that subsequently enable the determination of optimal treatment regimens in future studies with patient populations."

New P1 trial • Immunology

Anti-CD89 antibody for personalized treatment of IgA-mediated inflammatory disorders: Autoantigen-specific IgA, a biomarker with strong effector functions (FOB-USA 2024) - "JJP-1212 is a potential first-in-class IgG4 CD89 antagonist that inhibits binding and subsequent activation of CD89-positive myeloid cells by IgA. Additionally, JJP Biologics is developing serum-IgA-based companion diagnostics to stratify patients to provide them with a truly personalized treatment."

Biomarker • Immunology • Inflammation